Mitomycin (Mutamycin)
Jump to navigation
Jump to search
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anal cancer
- Bladder cancer
- Cervical cancer
- Cholangiocarcinoma
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Mesothelioma
Diseases for which is was used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/24/1981: Initial FDA approval
Also known as
- Generic names: mitomycin-C, MTC
- Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin
References
Categories:
- Drug index
- Intravenous medications
- Vesicant chemotherapy
- DNA synthesis inhibitors
- Anal cancer medications
- Bladder cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Esophageal cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Mesothelioma medications
- Drugs FDA approved in 1981